Teva Pharma (TEVA) Posts Q3 EPS of $0.89, Beats by 1c
Teva Pharmaceutical (NASDAQ: TEVA) reports Q3 EPS of $0.89, 1 cent better than the analyst estimate of $0.88. Revenue for the quarter was $3.55 billion, which compares to the estimate of $3.63 billion.
You May Also Be Interested In
- UPDATE: Auriga Starts Teva Pharma (TEVA) at Hold; Sidelined Until New CEO Is Convincing
- ATA, Inc. (ATAI) Misses Q4 EPS by 1c; Guides FY13 Revs Below
- Tiffany & Co. (TIF) Misses Q1 EPS by 1c; Lowers FY12 EPS, Revs Growth Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
